Development of endocrine therapy of breast cancer 1896-2006

Geburtshilfe und Frauenheilkunde

Volumn 67, Issue 6, 2007, Pages 595-601

  Howell, Anthony ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aromatase inhibitor; Fulvestrant; SERM; Tamoxifen

Indexed keywords

1,1,2 TRIPHENYLETHYLENE DERIVATIVE; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ACOLBIFENE; ANASTROZOLE; AROMATASE INHIBITOR; ARZOXIFENE; BUSERELIN; CLOMIFENE; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; DROLOXIFENE; EQUILENIN; ESTROGEN; ESTROGEN RECEPTOR; ETHAMOXYTRIPHETOL; EXEMESTANE; FULVESTRANT; GOSERELIN; IDOXIFENE; LETROZOLE; MEGESTROL ACETATE; MIPROXIFENE PHOSPHATE; PLACEBO; RALOXIFENE; TAMOXIFEN; TOREMIFENE;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER REGRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HISTORY; HUMAN; MONOTHERAPY; OVARIECTOMY; POSTMENOPAUSE; PREMENOPAUSE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 34547125990     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-965289     Document Type: Review

References (86)

1. Ahmed SR, Brooman PJ, Shalet SM, Howell A, Blacklock NJ, Rickards D. Treatment of advanced prostatic cancer with LHRH analogue ICI 118630: clinical response and hormonal mechanisms. Lancet 1983; 2: 415-419
2. Allen E, Doisy EA. An ovarian hormone: preliminary report on its localisation, extraction and partial purification and action in test animals. J AmerMed Assoc 1923; 81: 819-821
3. Allen JM, O'Shea JP, Mashiter K, Williams G, Bloom SR. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br Med J (Clin Res Ed) 1983; 286: 1607-1609
4. Anbazhagan R, Bartkova J, Nathan B, Gusterson BA. Extramedullary haematopoiesis in the human infant breast. The Breast 1992; 1: 182-186
5. Ascheim S, Zondek B. Hypophysenvorderlappenhormon und Ovarial-hormone im Harn von Schwangeren. Klin Wochenschr 1927; 6: 1322
6. Bachmann WE, Cole W, Wilde AL. The total synthesis of the sex hormone equilenin. J Amer Chem Soc 1939; 61: 974
7. Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 2: 450
8. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896; ii: 104-107
9. Bishop H. Sir George Beatson (1848-1933). The Breast 1992; 1: 179-181
10. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, Sahmoud T, Webster A, Steinberg M, Arimidex Writing Committee, Investigators Committee Members. Anastrozole is superior to tamoxifen as first line therapy in hormone receptor positive advanced breast cancinoma. Cancer 2001; 92: 2247-2258
11. Burrows H. Carcinoma mammae occuring in the male mouse under continued treatment with oestrin. Amer J Cancer 1935; 24: 613
12. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G. Phase II evaluation of Ly156758 in metastatic breast cancer. Oncology 1988; 45: 344-345
13. Clarke MJ. Ovarian ablation in breast cancer, 1896 to 1998: milestones along hierarchy of evidence from case report to Cochrane review. BMJ 1998; 317: 1246-1248
14. Coates AS, Keshaviah A, Thurlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492
15. Cole MP, Jones CTA, Todd IDH. A new antioestrogenic agent in late breast cancer: an early clinical appraisal of ICI 146474. Brit Journal of Ca 1971; 25: 270-275
16. Coombes RC, Goss P, Dowsett M, Gazet J-C, Brodie A. 4-hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer. Lancet 1984; 11: 1237-1239
17. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Eng J Med 2004; 350: 1081-1092
18. Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, van de Velde CJ, Delozier T, Alvarex I et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369: 559-570
19. Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol 2005; 23: 1636-1643
20. DeCourmelles FV. La radiotherapie indirecte ou dirigee par les correlations organiques. Archives d'Electricite Medical 1922; 32: 264
21. Dodds EC, Goldberg L, Lawson W, Robinson R. Oestrogenic activity of certain synthetic compounds. Nature 1938; 141: 247-248
22. Doisy EA, Veler CD, Thayer S. Folliculin from urine of pregnant women. Amer J Physiol 1929; 90: 329-330
23. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J, Bezwoda W, Gardin G, Gudgeon A, Morgan M et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: a double blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-461
24. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996; 347: 1066-1071
25. Early Breast Cancer Trialists Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717
26. Folca PJ, Glascock RF, Irvine WT. Studies with tritium-labelled hexoestrol in advanced breast cancer. Comparison of tissue accumulation of hexoestrol with response to bilateral adrenalectomy and oophorectomy. Lancet 1961; 1: 795-798
27. Gardner WU, Strong LC, Smith GM. The mammary glands of mature female mice of strains varying in susceptibility to spontaneous tumour development. Amer J Cancer 1939; 37: 510-517
28. Goormaghtigh N, Amerlinck A. Realisation experimentale de la maladie de recluse de la mamelle chez la souris. Bulletin du Cancer 1930; 14: 527-543
29. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI et al. A randomised trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 2003; 349: 1793-1802
30. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB. Preliminary trial of aminoglutethimide in breast cancer. Cancer 1973; 32: 31-37
31. Haddow A, Watkinson JM, Patterson E. Influence of synthetic oestrogens upon advanced malignant disease. British Med Journal 1944; 2: 393-398
32. Harper MJ, Walpole AL. Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 1966; 212: 87
33. Hegar A. Die castration der Frauen. Leipzig: Breitkopf und Hartel, 1878: 978
34. Howell A, DeFriend D, Robertson J, Blamey R, Watson R, Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen resistant breast cancer. Lancet 1995; 345: 29-30
35. Howell A, Downey S, Anderson E. New endocrine therapies for breast cancer. Eur Journal Cancer 1996; 32a: 576-589
36. Howell A, Clarke RB, Anderson E. Oestrogens, Beatson and endocrine therapy. Endocrine-Related Cancer 1997; 4: 371-380
37. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403
38. Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomised trial. J Clin Oncol 2004; 22: 1605-1613
39. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias J, ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62
40. Howell A, Locker GY. Defining the roles of aromatase inhibitors in the adjuvant treatment of early stage breast cancer. Clin Breast Cancer 2005; 6: 302-309
41. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006; 13: 689-706
42. Huggins C, Dao TL. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. J Am Med Assoc 1953; 151: 1388-1394
43. Huggins C. Two principles in endocrine therapy of cancers: hormone deprival and hormone interference. Cancer Research 1965; 25: 1163-1167
44. Iveson TJ, Smith IE, Ahern IE, Smithers DA, Turnet PF, Dowsett M. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993; 15: 266-270
45. Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H et al. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462
46. Jensen EV, DeSombre ER, Hurst DJ, Kawashima T, Jungblut PW. Estrogen receptor interactions in target tissue. Archives of Anatomy, Microscopy & Morphological Exp 1967; 56: 547-569
47. Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Janicke F, Njordenskold B, Forbes JF et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre and perimenopausal patients with advanced breast cancer. Eur J Cancer 1995; 31A: 137-142
48. Jonat W, Howell A, Blomqvist C, Eiermann W, Winbald G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32a: 404-412
49. Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A et al, Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate and fluorouracil as adjuvant therapy in premenopausal patients with node positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002; 20: 4628-4635
50. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone sensitive early stage breast cancer: a meta-analysis. Lancet Oncol 2006; 7: 991-996
51. Jordan VC. Effect on tamoxifen (ICI 146,474) on initiation and growth of DMBA-induced rat mammary carcinoma. Euro Journal of Cancer 1976; 12: 419-424
52. Kaufmann M, Jonat W, Kleeberg U, Eiermann W, Janicke F, Hilfrich J, Kreienberg R, Albrecht M, Weitzel HK, Schmid H et al., German Zoladex Trial Group. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. J Clin Oncol 1989; 7: 1113-1119
53. Kaufmann M, Jonat W, Schachner-Wunschmann E, Bastert G, Maass H on behalf of the Cooperative German Zoladex Study Group. The depot GnRH analogue goserelin in the treatment of premenopausal patients with metastatic breast cancer - a 5 year experience and further endocrine therapies. Onkologie 1991; 14: 22-30
54. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J et al., The Exemestane Study Group. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomised double blind trial. J Clin Oncol 2000; 18: 1399-1411
55. Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W, Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists Group. Survival analyses from the ZEBRA study. Goserelin (Zoladex) versus CMF in premenopausal women with node positive breast cancer. Eur J Cancer 2003; 39: 1711-1717
56. Klijn JG, de Jong FH. Treatment with luteinising-hormone- releasing-hormone analogue (buserelin0 in premenopausal patients with metastatic breast cancer. Lancet 1982; 1: 1213-1216
57. Klijn JG, Beex LV, Mauriac L, van Ziji JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau J. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomised study. J Natl Cancer Inst 2000; 92: 903-911
58. Klijn J, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R, Combined Agents Trialists Group and the European Organisation for Research and Treatment of Cancer. Combined tamoxifen and luteinising hormone releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomised trials. J Clin Oncol 2001; 19: 343-353
59. Lacassagne A. Apparition de cancers de la mamelle chez la souris male, soumise a des injections de folliculine. Comptes Rendus de L'Academic des Sciences Series III 1932; 195: 630-632
60. Lacassagne A. Sur la pathologenie de l'adenocarcinoma mammaire de la souris. Comptes Rendus de Biologie et de ses Fileiles 1934; 115: 937-939
61. Lacassagne A. Statisque des differents cancers constates dans les lignes selectionnes de souris apres action prolongee d'hormones oestrogenes. Assoc Français Etudes Cancer 1938; 27: 96-98
62. Lathrop ABC, Loeb L. Further investigations on the origins of tumours in mice III. On the part played by internal secretion in the spontaneous development of tumours. Journal of Ca Research 1916; 1: 1-19
63. Loeb L, Blumenthal HT, Kirtz MM. The effectiveness of ovarian and hypophysial grafts in the production of mammary carcinoma in mice. Science 1944; 99: 230-233
64. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, Mella O, Howell A. High dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001; 67: 111-116
65. Love RR, Philips J. Oophorectomy for breast cancer: history revisited. JNCI 2002; 94: 1433-1434
66. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Janicke F et al. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer: results of a phase II study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606
67. Nunn TW. On cancer of the breast. London: J & A Churchill, 1882: 71
68. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-750
69. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertier SZ, May JT, Burton G, Dimery I et al. Double blind randomised trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-3395
70. Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A et al. Mature results of a randomised phase II multicenter study of exemestane versus tamoxifen as first line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14: 1391-1398
71. Paterson R. Breast cancer. A report of two clinical trials. J R Coll Surg 1962; 7: 243-254
72. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL. Randomised trial of diethylstilbestrol v tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast cancer Res Treat 1999; 54: 117-122
73. Pyrhonen S, Ellmen J, Vuorinen J, Gershanovich M, Tominaga T, Kaufmann M, Hayes DF. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56: 133-143
74. Rody A, Loibl S, von Minckwitz G, Kaufmann M. Use of goserelin in the treatment of breast cancer. Expert Rev Anticancer Ther 2005; 5: 591-604
75. Schinzinger A, Maxfield WS. Ueber carcinoma mammae. Zent Org Gesamle Chir 1889; 29: 55-57
76. Schinzinger A. Ueber carcinoma mammae (abstract). 18th Congress of the German Society for Surgery. Beilage zum Centralblatt fur Chirurgie 1889; 16: 55-56
77. Schinzinger A. Ueber carcinoma mammae (abstract). Verhandlungen der Deutschen Gesellschaft fur Chirurgie. 18th Congress, Berlin 24-27 April 1889. Hirschwald, 1889: 28
78. Ulrich P. Testosterone et son role possible dans le traitment de certains cancers du sein. Union Against Cancer 1939; 4: 377
79. Wakeling AE, Bowler J. ICI 182, 780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 1992; 43: 173-177
80. Walker KJ, Nicholson RI, Turkes AO, Turkes A, Griffiths K, Robinson M, Crispin Z, Dris S. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma. Lancet 1983; 2: 413-415
81. Walpole AL, Patterson E. Synthetic oestrogens in mammary cancer. Lancet 1949; 2: 783-786
82. Wells SA Jr, Worgul TJ, Samojilik E, Boucher AE, Lipton A, Harvey H, White D, Smart E, Cox C, Santen RJ. Comparison of surgical adrenalectomy to medical adrenalectomy in patients with metastatic carcinoma of the breast. Cancer Res 1982; 42: 3454 s-3457 s
83. Williams MR, Walker KJ, Turkes A, Blamey RW, Nicholson RI. The use of an LHRH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 1986; 53: 629-636
84. Zilembo N, Noberasco C, Bajetta E, Martinetti A, Mariani L, Orefice S, Buzzoni R, Di Bartolomeo M, Di Leo A, Laffranchi A et al. Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. Br J Cancer 1995; 72: 1007-1012
85. DeFriend D, Howell A, Nicholson RI, Anderson E, Dowsett M, Mansel RE, Blamey RW, Bundred NJ, Robertson JF, Saunders C, Baum M, Walton P, Sutcliffe F, Wakeling AE. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Research 1994; 54: 408-414
86. Gradishar WJ, Cella D. Selective estrogen receptor modulators and prevention of invasive breast cancer. JAMA 2006; 295: 2784-2786